The advent of chimeric antigen receptor (CAR) T-cell therapy offers a new therapeutic avenue for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL) up to the age of 25 years, or diffuse large B-cell lymphoma (DLBCL) in adult patients. However, CAR-T therapy is associated with significant and unique toxicities that require specialised monitoring ...
Managing the complexities of CAR-T therapy in patients with leukaemia and lymphoma
19 Jul 2021
Sponsored by Novartis Pharmaceuticals Australia Pty Ltd